 WASHINGTON, May 5, 2021 PRNewswire -- Vanda Pharmaceuticals Inc. Vanda Nasdaq: VNDA today announced financial and operational results for the first quarter ended March 31, 2021. Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of HETLIOZ in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome, said Mihael H. 